MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
23 janv. 2023 06h05 HE
|
MannKind
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side...
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
05 janv. 2023 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative...
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
10 nov. 2022 06h05 HE
|
MannKind
Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulinsThe Afrezza with Basal Combination...
MannKind Corporation Reports 2022 Third Quarter Financial Results
08 nov. 2022 08h00 HE
|
MannKind
3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 20213Q 2022 Royalties from Tyvaso DPI of $6.2 million3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and...
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
01 nov. 2022 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its...
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
21 sept. 2022 17h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
06 sept. 2022 06h15 HE
|
MannKind
Study supports the dosing regimen that will be pursued in further clinical programsNo serious adverse events or QT prolongation identifiedPlanning underway to discuss results and the ongoing clinical...
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
01 sept. 2022 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
MannKind Corporation Reports 2022 Second Quarter Financial Results
09 août 2022 16h00 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere® inhalation platform V-Go® acquired May...
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
02 août 2022 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its...